Tuberculosis vaccine: A journey from BCG to present

被引：103

作者：

Fatima, Samreen ^{[1
]}

Kumari, Anjna ^{[2
]}

Das, Gobardhan ^{[1
]}

Dwivedi, Ved Prakash ^{[2
]}

机构：

[1] Jawaharlal Nehru Univ, Special Ctr Mol Med, New Delhi, India

[2] Int Ctr Genet Engn & Biotechnol, Immunobiol Grp, New Delhi, India

来源：

LIFE SCIENCES | 2020年 / 252卷

关键词：

Mycobacterium tuberculosis; Vaccine; T helper cells; BCG; Cytokines; Memory cells; PROTECTION; IMMUNITY; PREVENTION; INDUCTION; INFECTION; EFFICACY; FAILURE; CELLS; TRIAL;

D O I：

10.1016/j.lfs.2020.117594

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Tuberculosis (TB) is the leading cause of death worldwide due to an infectious disease, causing around 1.6 million deaths each year. This situation has become more complicated by the emergence of drug-resistant Mycobacterium tuberculosis (M.tb) and HIV-TB co-infection, which has significantly worsened TB prognosis and treatment. Despite years of intensive research, Bacille Calmette-Guerin (BCG) remains the only licensed vaccine and has variable efficacy. It provides protection against childhood TB but is not effective in adult pulmonary TB. As a result of intense research in understanding TB vaccinology, there are many new vaccine candidates in clinical development and many more in pre-clinical trials which aim either to replace or boost BCG vaccine. This review discusses the history of BCG vaccine development and summarizes limitations of the current vaccine strategy and recent advances in improving BCG immunization along with other new vaccines in clinical trials which are promising candidates for the future tuberculosis vaccinology program.

引用

页数：10

共 56 条

[1] IgA and IgG against Mycobacterium tuberculosis Rv2031 discriminate between pulmonary tuberculosis patients, Mycobacterium tuberculosis-infected and non-infected individuals [J].

Abebe, Fekadu ;

Belay, Mulugeta ;

Legesse, Mengistu ;

Franken, K. L. M. C. ;

Ottenhoff, Tom H. M. .

PLOS ONE, 2018, 13 (01)

[2]

Ahsan Mohamed Jawed, 2015, Ther Adv Vaccines, V3, P66, DOI 10.1177/2051013615593891

[3] Updates on the risk factors for latent tuberculosis reactivation and their managements [J].

Ai, Jing-Wen ;

Ruan, Qiao-Ling ;

Liu, Qi-Hui ;

Zhang, Wen-Hong .

EMERGING MICROBES & INFECTIONS, 2016, 5

[4]

ANACKER RL, 1972, Z IMMUNITATSFORSCH, V143, P363

[5] The success and failure of BCG - implications for a novel tuberculosis vaccine [J].

Andersen, P ;

Doherty, TM .

NATURE REVIEWS MICROBIOLOGY, 2005, 3 (08) :656-662

[6] Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials [J].

Arbues, Ainhoa ;

Aguilo, Juan I. ;

Gonzalo-Asensio, Jesus ;

Marinova, Dessislava ;

Uranga, Santiago ;

Puentes, Eugenia ;

Fernandez, Conchita ;

Parra, Alberto ;

Cardona, Pere Joan ;

Vilaplana, Cristina ;

Ausina, Vicente ;

Williams, Ann ;

Clark, Simon ;

Malaga, Wladimir ;

Guilhot, Christophe ;

Gicquel, Brigitte ;

Martin, Carlos .

VACCINE, 2013, 31 (42) :4867-4873

[7]

ARONSON JD, 1948, AM REV TUBERC PULM, V58, P255

[8]

Barberis I, 2017, J Prev Med Hyg, V58, pE9

[9] Failure of the Mycobacterium bovis BCG vaccine:: Some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis [J].

Brandt, L ;

Cunha, JF ;

Olsen, AW ;

Chilima, B ;

Hirsch, P ;

Appelberg, R ;

Andersen, P .

INFECTION AND IMMUNITY, 2002, 70 (02) :672-678

[10] RUTI: A new chance to shorten the treatment of latent tuberculosis infection [J].

Cardona, Pere-Joan .

TUBERCULOSIS, 2006, 86 (3-4) :273-289

← 1 2 3 4 5 6 →